Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate(RIS) With Vertebral Fracture as an Index -

NCT00447915 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT00447915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00447915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate(RIS) With Vertebral Fracture as an Index -
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2007
Completion date
December 31, 2011
Enrollment
1,265 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

primary osteoporosis